Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 3/2012

01-02-2012 | Erratum

Erratum to: Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis

Authors: Theodoros N. Sergentanis, Konstantinos P. Economopoulos

Published in: Breast Cancer Research and Treatment | Issue 3/2012

Login to get access

Excerpt

The authors would like to replace the typographical error “Thr461Asp” by “Thr461Asn” throughout the article. …
Metadata
Title
Erratum to: Four polymorphisms in cytochrome P450 1A1 (CYP1A1) gene and breast cancer risk: a meta-analysis
Authors
Theodoros N. Sergentanis
Konstantinos P. Economopoulos
Publication date
01-02-2012
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-010-1079-5

Other articles of this Issue 3/2012

Breast Cancer Research and Treatment 3/2012 Go to the issue

Epidemiology

Appendectomy and cancer risk in Jewish BRCA1 and BRCA2 mutation carriers

Preclinical study

Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer

Preclinical Study

LDH-A silencing suppresses breast cancer tumorigenicity through induction of oxidative stress mediated mitochondrial pathway apoptosis

Letter to the Editor

Parity and mortality from causes other than breast cancer in breast cancer patients

Epidemiology

Adjuvant therapy, not mammographic screening, accounts for most of the observed breast cancer specific mortality reductions in Australian women since the national screening program began in 1991

Preclinical study

Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits